APA

Ciruelos E., Apellániz-Ruiz M., Cantos B., Martinez-Jáñez N., Bueno-Muiño C., Echarri M., Enrech S., Guerra J., Manso L., Pascual T., Dominguez C., Gonzalo J., Sanz J., Rodriguez-Antona C. & Sepúlveda J. (20200701). A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. : The oncologist.

Chicago

Ciruelos Eva, Apellániz-Ruiz María, Cantos Blanca, Martinez-Jáñez Noelia, Bueno-Muiño Coralia, Echarri Maria-Jose, Enrech Santos, Guerra Juan-Antonio, Manso Luis, Pascual Tomas, Dominguez Cristina, Gonzalo Juan-Francisco, Sanz Juan-Luis, Rodriguez-Antona Cristina and Sepúlveda Juan-Manuel. 20200701. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. : The oncologist.

Harvard

Ciruelos E., Apellániz-Ruiz M., Cantos B., Martinez-Jáñez N., Bueno-Muiño C., Echarri M., Enrech S., Guerra J., Manso L., Pascual T., Dominguez C., Gonzalo J., Sanz J., Rodriguez-Antona C. and Sepúlveda J. (20200701). A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. : The oncologist.

MLA

Ciruelos Eva, Apellániz-Ruiz María, Cantos Blanca, Martinez-Jáñez Noelia, Bueno-Muiño Coralia, Echarri Maria-Jose, Enrech Santos, Guerra Juan-Antonio, Manso Luis, Pascual Tomas, Dominguez Cristina, Gonzalo Juan-Francisco, Sanz Juan-Luis, Rodriguez-Antona Cristina and Sepúlveda Juan-Manuel. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. : The oncologist. 20200701.